ERBB2 and breast carcinoma: Baseline patient characteristics and the characteristics of the breast cancer and treatment line did not differ significantly between the two groups, including biomarkers such as hormone receptors and HER2, the distribution of breast cancer, the treatment line of eribulin and the objective response to eribulin (Table 1).